All In Biotech

Drug Trial Radar · NCT04471298

A Study of Qishenyiqi Dripping Pills in Healthy Participants

A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Phase 1 Study to Evaluate the Safety and Tolerability of Continuous Oral Treatment With Qishenyiqi Dripping Pills in Healthy Participants

Last checked: Nov 20, 2026Latest source record: Jul 14, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

36

Actual

Start

Sep 21, 2020

Primary completion

Jan 11, 2021

Study completion Jan 11, 2021

Sponsor

Sponsor type
Industry
First posted
Jul 15, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Other
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study will evaluate the safety and tolerability of Qishenyiqi Dripping Pills in healthy participants, following oral administration with multiple escalating dose of it.

Conditions

  • Healthy Participants

Interventions

  • Qishenyiqi dripping pills, 6 bagsDrug

    28 consecutive days

  • Qishenyiqi dripping pills, 9 bagsDrug

    28 consecutive days

  • Qishenyiqi dripping pills, 12 bagsDrug

    28 consecutive days

  • Qishenyiqi dripping pills placebo, 6 bagsDrug

    28 consecutive days

  • Qishenyiqi dripping pills placebo, 9 bagsDrug

    28 consecutive days

  • Qishenyiqi dripping pills placebo, 12 bagsDrug

    28 consecutive days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse eventsTime frame: From screening (2 weeks in advance) till follow-up visit (up to 1week)
  2. Number of participants with abnormal vital signs index (body temperature)Time frame: From screening (2 weeks in advance) till the end of trial period (Day 29)
  3. Number of participants with abnormal vital signs index (pulse rate)Time frame: From screening (2 weeks in advance) till the end of trial period (Day 29)
  4. Number of participants with abnormal vital signs index (respiratory rate)Time frame: From screening (2 weeks in advance) till the end of trial period (Day 29)
  5. Number of participants with abnormal vital signs index (blood pressure)Time frame: From screening (2 weeks in advance) till the end of trial period (Day 29)
  6. Physical examinationTime frame: screening (2 weeks in advance), Day 8, Day 15, Day 22, Day 29
  7. Number of participants with abnormal laboratory assessments (blood routine test)Time frame: screening (2 weeks in advance), Day 8, Day 15, Day 22, Day 29
  8. Number of participants with abnormal laboratory assessments (blood biochemical test)Time frame: screening (2 weeks in advance), Day 8, Day 15, Day 22, Day 29
  9. Number of participants with abnormal laboratory assessments (coagulation function test)Time frame: screening (2 weeks in advance), Day 8, Day 15, Day 22, Day 29
  10. Number of participants with abnormal laboratory assessments (urinalysis routine test)Time frame: screening (2 weeks in advance), Day 8, Day 15, Day 22, Day 29
  11. Number of participants with abnormal laboratory assessments (fecal routine test)Time frame: screening (2 weeks in advance), Day 8, Day 15, Day 22, Day 29
  12. Number of participants with abnormal findings in 12-lead safety Electrocardiogram (ECG)Time frame: screening (2 weeks in advance), Day 8, Day 15, Day 22, Day 29

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First Teaching Hospital of Tianjin University of TCM

    Tianjin, Tianjin Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.